secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0000950170-25-003832
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular reports positive 32-week DME data; FDA aligns on single Phase 3; cash runway into 2028
--------------------------------------------------------------------------------

- Cash, equivalents, securities $506M as of Dec 31; cash runway extended to 2028.
- SPECTRA Part 1 (DME): 4D-150 well tolerated, no intraocular inflammation; high dose +8.4 letters BCVA, -194 µm CST; mean 0.6 supplemental injections vs 4.0 for aflibercept.
- FDA: single Phase 3 trial (300-400 patients) acceptable for BLA for 4D-150 in DME; SPECTRA Part 2 no longer needed.
- Pipeline refocus: core 4D-150 (wet AMD/DME) and 4D-710 (CF); discontinue 4D-110 and 4D-125; reduce investment in 4D-175/725/310 pending partnerships.
- Phase 3 4FRONT trials for wet AMD start Q1 and Q3 2025; topline data expected H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/0000950170-25-003832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/fdmt-20250110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-003832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer